Former HealthSouth CEO Richard Scrushy and others have been ordered to turn over records and documents related to a bank account which lawyers say the convicted executive was using to hide millions.
https://t.co/OsuFDBbq6T
55TTJkfjEKWANYZw47BqU1x6SjzD5gYNbLqXPuwApump #pump#pumpfun MetaOptics Ltd (MOT) MetaOptics is a vertically integrated metalens technology company, combining core competencies across metalens equipment, foundry, products, and metaoptics artificial intelligence.
We conduct our operations through our wholly-owned subsidiaries in Singapore and the United States. Our operations are centered on the design and manufacture of metalenses and metalens prototypes, and to demonstrate the viability, efficacy, applications and use cases of our metalenses, we have expanded our operations to include the development of metalens camera modules and metalens Internet of Things products, such as infrared metalens cameras, pico projectors, and IoT metalens color cameras.
Our metalenses have also been integrated into a wide range of applications by our customers, including fifth generation smartphones, contactless three-dimensional biometric modules, projectors, and for industrial applications such as IoT devices, light detection and ranging (“LiDAR”) devices and heads-up displays (“HUDs”) for planes and self-driving cars, and augmented reality/virtual reality devices.
$MOT
Lyntris is a leading defense technology company delivering “sense-to-act” connectivity solutions for the modern, connected battlespace.
Our solutions enable both U.S. and allied nation warfighters to detect threats earlier, decide faster and act with precision in contested, multi-domain environments.
Our solutions are deployed across three high-growth core missions: Maritime Domain Awareness; Air & Missile Defense; and Space Intelligence, Surveillance, Reconnaissance & Resilient Communications.
In 2025, we supported more than 200 DoW and allied nation programs with no program accounting for more than 7% of our total revenue. Lyntris Inc. $LYNX
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Braveheart Bio jumped 68% in its trading debut, after the clinical-stage biopharmaceutical company backed by a16z raised $382.5 million in an upsized US IPO https://t.co/K9ruCZpRHE
Londian Wason New Energy Tech is a leading global innovation-driven researcher, developer, and manufacturer of electrolytic copper foil. We primarily offer LiB copper foil and PCB-grade copper foil, and to a lesser extent, FCCLs (Flexible Copper Clad Laminate). Our copper foil is utilized in end markets including electric vehicles, or EVs, energy storage systems, or ESSs, and a broad spectrum of other downstream applications such as communication equipment and consumer electronics
Ticketplus is a technology company focused on powering the live entertainment industry across Latin America.
We provide a proprietary, full-stack event platform that supports event discovery, primary ticketing, access control, payments, analytics, and post-event insights for promoters, venues, sports organizations, and ticketing companies.
Since our founding in 2014 in Chile, we have expanded through a dual business model strategy: (1) a full-operations model in Chile, our home market, where we act as the primary ticketing platform and deliver end-to-end infrastructure and services and (2) a white-label software-as-a-service, or SaaS, model where we license our platform to regional ticketing companies, venues, and promoters who operate under their own brands while using our technology.
Our platform is designed to increase attendance and maximize revenue for our clients by combining reliable transaction processing with data-driven pricing, personalization, and conversion-optimized experiences. $TP
Jersey Mike's Subs Inc. engages in franchising and operating fast casual, submarine-style sandwich restaurants specializing in authentic, hand-crafted, and craveable subs. The company also offers catering services, as well as provides mobile app, online ordering, and third-party delivery. It operates stores in the United States and Canada, as well as franchise agreements in the United Kingdom and Ireland. The company was founded in 1956 and is based in Tinton Falls, New Jersey. $JMKE BSwVnZiMXmbDBd5KizJtYG4VYTErkxEM5mMY92JRpump
Flock Safety, Inc.
Ticker: FLOCK
Flock Safety is a leading AI-powered public safety technology company specializing in automated license plate recognition, smart security cameras, real-time crime detection, drones, and cloud-based investigative software. Through a subscription-based platform, Flock connects law enforcement agencies, businesses, schools, neighborhoods, and enterprise security teams with powerful AI tools designed to help prevent and solve crime.
Investment Highlights
AI-powered license plate recognition network
Subscription-based recurring revenue model
Expanding into drones, gunshot detection, and real-time operations software
Trusted by thousands of public and private organizations
Rapid growth with a multi-billion-dollar private valuation
Products
Automated License Plate Recognition (ALPR)
AI Security Cameras
Gunshot Detection
Drone as First Responder
Mobile Security Trailers
Cloud Investigation Platform
AI Search & Analytics
Customers
Law Enforcement
Schools
Businesses
Retail Centers
Commercial Real Estate
Homeowner Associations
Enterprise Security
Braveheart Bio is a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases.
Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non‑obstructive HCM.
Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui.
#Pumpfun #Solana 2b8qSDx4tWDJHNEVg3RRBRNqARR9xmtHXLhaDNp3pump